BioXcel Therapeutics (BTAI) executive compensation, 2025 proxy

Vimal Mehta, Ph.D., Chief Executive Officer, was paid $1.1M in 2024, down 76% from $4.7M the year before.

Filed
November 12, 2025
Annual meeting
December 12, 2025
Pay year
2024
Named executives
3
CEO total pay
$1.1M-76% vs prior year
2024 CEO Total Pay
$1,119,245Decreased from prior year
2024 CEO Salary
$1,001,570Unchanged from 2023

How Ph.D. was paid

$1.1M in total for 2024, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary89%Option awards9%All other compensation1%

Named executive officers

ExecutiveTotal
Vimal Mehta, Ph.D.Chief Executive Officer$1,119,245
Javier RodriguezSenior VP and Chief Legal Officer$1,012,552
Richard SteinhartSVP and Chief Financial Officer$998,216

What changed and why

  • $1.1MChief executive officer total compensation decreased to $1,119,245 in 2024 from $4,731,147 in 2023.
  • Base salaries for named executive officers were not increased in 2024 by the compensation committee.
  • No annual cash bonuses were awarded to named executive officers for 2024 performance.
  • Credit agreement restrictions prevented the payment of cash bonuses and increases in 2025 cash compensation.
  • Performance-based restricted stock units and stock options were granted as long-term incentives.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.